Table 1.

Demographic, Clinical, and CNS-Active–Drug Characteristics in Patients with RBD

Patients with idiopathic RBD	1	2	3	4	5	6	7	8
Age, y	73	72	72	67	67	62	68	63
Sex	m	m	m	m	f	m	m	m
RBD duration, y	4	4	7	12	7	20	10	3
Patients with secondary RBD due to PD	1	2	3	4	5	6	7	8	9
Age, y	63	43	45	57	63	67	47	53	51
Sex	m	f	m	f	m	m	f	m	m
Hoehn – Yahr stage in “on”	1.5	2.5	3	3	3	2	3	3	4
Age at onset of parkinsonism, y	60	39	33	50	58	57	43	44	30
RBD duration, y	3	1	2	7	2	10	3	5	3
Daily levodopa equivalent dose, mg	0	405	600	1060	1065	1000	535	1200	1420
Antidepressants	Isocarboxazide	-	-	-	-	-	Amitriptyline	-	-
Atypical neuroleptics	-	-	-	-	Quetiapine	-	-	Quetiapine	-
Hypnotics	-	-	-	Bromazepam	-	-	-	Zolpidem	Zolpidem
Timing of RBD onset as related to treatment onset with CNS active drugs	After	After	After	After	After	Before	After	After	After
Clinical effect of different medications on RBD symptoms	No effecta	No effecta	No effecta	No effecta	No effecta	No effecta	No effecta	No effecta	No effecta

m refers to male; f, female; PD: Parkinson disease

^aRapid eye movement sleep behavior disorder (RBD) symptoms persisted after discontinuation of previous central nervous system (CNS) active medication.